DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
Authors
Keywords
-
Journal
Frontiers in Genetics
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-08-16
DOI
10.3389/fgene.2019.00724
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A potential biomarker for anti-PD-1 immunotherapy
- (2018) Sangeeta Goswami et al. NATURE MEDICINE
- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
- (2018) Lucas Ferrari de Andrade et al. SCIENCE
- Enhancing responses to cancer immunotherapy
- (2018) Pia Kvistborg et al. SCIENCE
- Immune Checkpoint Inhibition in Head and Neck Cancer
- (2018) Martin David Forster et al. Frontiers in Oncology
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Trends in the global immuno-oncology landscape
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
- (2017) Arnaud Scherpereel et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA methylation in the tumor microenvironment
- (2017) Meng-wen Zhang et al. Journal of Zhejiang University-SCIENCE B
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- The benefits of immunotherapy combinations
- (2017) Charles Schmidt NATURE
- OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
- (2017) D. A. Reardon et al. NEURO-ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
- (2017) Vinay Prasad et al. SEMINARS IN ONCOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Microsatellite Instability
- (2017) Liisa Chang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation
- (2016) Qian Xiao et al. CANCER RESEARCH
- Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
- (2016) Carolina Pereira et al. CLINICAL CANCER RESEARCH
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses
- (2016) Patrick J. Medina et al. PHARMACOTHERAPY
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
- (2015) F. Sabbatino et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A draft network of ligand–receptor-mediated multicellular signalling in human
- (2015) Jordan A. Ramilowski et al. Nature Communications
- MR1 presents microbial vitamin B metabolites to MAIT cells
- (2012) Lars Kjer-Nielsen et al. NATURE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- STRING v9.1: protein-protein interaction networks, with increased coverage and integration
- (2012) Andrea Franceschini et al. NUCLEIC ACIDS RESEARCH
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Cancer epigenetics: linking basic biology to clinical medicine
- (2011) Hsing-Chen Tsai et al. CELL RESEARCH
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started